These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 16966616)

  • 1. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
    Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
    Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
    Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
    Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
    Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
    Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.
    Craven ER; Walters TR; Williams R; Chou C; Cheetham JK; Schiffman R;
    J Ocul Pharmacol Ther; 2005 Aug; 21(4):337-48. PubMed ID: 16117698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
    Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
    Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
    Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
    Goñi FJ;
    Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
    Katz G; Dubiner H; Samples J; Vold S; Sall K
    JAMA Ophthalmol; 2013 Jun; 131(6):724-30. PubMed ID: 23579344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures.
    Solish AM; DeLucca PT; Cassel DA; Kolodny AH; Hustad CM; Skobieranda F
    J Glaucoma; 2004 Apr; 13(2):149-57. PubMed ID: 15097262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
    Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
    Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.
    Frampton JE
    Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
    Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
    Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phase III clinical trial of brimonidine in patients with primary open-angle glaucoma and ocular hypertension--comparison of the effects of brimonidine monotherapy versus timolol monotherapy, or combination brimonidine/prostaglandins therapy versus combination placebo/prostaglandins therapy].
    Araie M; Yamazaki Y; Sugiyama K; Kuwayama Y; Tanihara H
    Nippon Ganka Gakkai Zasshi; 2012 Oct; 116(10):955-66. PubMed ID: 23285843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
    Shin DH; Feldman RM; Sheu WP;
    Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.